Beijing Tong Ren Tang Chinese Medicine FY26 H1 profit attributable to owners drops 15.6% to HK$ 198.2 million; revenue falls 21% to HK$ 601.89 million

PUBT · 2d ago
Beijing Tong Ren Tang Chinese Medicine FY26 H1 profit attributable to owners drops 15.6% to HK$ 198.2 million; revenue falls 21% to HK$ 601.89 million
  • Beijing Tong Ren Tang Chinese Medicine revenue fell 21% to HK$ 601.89 million for the six months ended June 30, 2026.
  • Profit attributable to owners slipped 15.6% to HK$ 198.2 million; earnings per share eased to HK$ 0.24.
  • Gross margin widened 3.1 percentage points to 63.9%, with management citing cost controls and a product-mix shift.
  • Cash and bank balances edged down 3.1% to HK$ 2.21 billion; the board did not recommend an interim dividend.
  • Group launched Ganoderma Liver Detox Pro and Antelope Horn Powder Capsules; Tai Po base secured Vietnam GMP certification for market entry.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beijing Tong Ren Tang Chinese Medicine Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260828-12305496), on August 28, 2026, and is solely responsible for the information contained therein.